Welcome!

News Feed Item

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html

Fatty Liver Disease Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Fatty Liver Disease Global Clinical Trials Review, H2, 2014" provides data on the Fatty Liver Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatty Liver Disease. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fatty Liver Disease. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Fatty Liver Disease 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Fatty Liver Disease 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Fatty Liver Disease Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Fatty Liver Disease 33
Jul 30, 2014: Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 33
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 34
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Merck & Co., Inc. 35
Clinical Trial Overview of Merck & Co., Inc. 35
Galmed International Ltd. 36
Clinical Trial Overview of Galmed International Ltd. 36
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
PharmaKing Co., Ltd. 38
Clinical Trial Overview of PharmaKing Co., Ltd. 38
Abbott Laboratories 39
Clinical Trial Overview of Abbott Laboratories 39
TCM Biotech International Corp 40
Clinical Trial Overview of TCM Biotech International Corp 40
Sanofi 41
Clinical Trial Overview of Sanofi 41
Phenex Pharmaceuticals AG 42
Clinical Trial Overview of Phenex Pharmaceuticals AG 42
GW Pharmaceuticals plc 43
Clinical Trial Overview of GW Pharmaceuticals plc 43
Genextra S.p.a. 44
Clinical Trial Overview of Genextra S.p.a. 44
Clinical Trial Overview of Top Institutes / Government 45
The National Institute of Diabetes and Digestive and Kidney Diseases 45
Clinical Trial Overview of The National Institute of Diabetes and Digestive and Kidney Diseases 45
Tabriz University of Medical Sciences 46
Clinical Trial Overview of Tabriz University of Medical Sciences 46
Third Military Medical University 47
Clinical Trial Overview of Third Military Medical University 47
University of Michigan 48
Clinical Trial Overview of University of Michigan 48
Tehran University of Medical Sciences 49
Clinical Trial Overview of Tehran University of Medical Sciences 49
Washington University School of Medicine 50
Clinical Trial Overview of Washington University School of Medicine 50
University of California, San Diego 51
Clinical Trial Overview of University of California, San Diego 51
FUDAN University 52
Clinical Trial Overview of FUDAN University 52
Ahvaz Jundishapur University of Medical Sciences 53
Clinical Trial Overview of Ahvaz Jundishapur University of Medical Sciences 53
Bambino Gesu Hospital and Research Institute 54
Clinical Trial Overview of Bambino Gesu Hospital and Research Institute 54
Five Key Clinical Profiles 55
Appendix 82
Abbreviations 82
Definitions 82
Research Methodology 83
Secondary Research 84
About GlobalData 84
Contact Us 84
Disclaimer 84
Source 85

List of Tables
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Region, 2014* 7
Fatty Liver Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Fatty Liver Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Fatty Liver Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Fatty Liver Disease Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Fatty Liver Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Fatty Liver Disease Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2014* 15
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2014* 18
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Fatty Liver Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Fatty Liver Disease Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Fatty Liver Disease Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Fatty Liver Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Fatty Liver Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Fatty Liver Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Fatty Liver Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Fatty Liver Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 35
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Galmed International Ltd., 2014* 36
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 37
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by PharmaKing Co., Ltd., 2014* 38
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Abbott Laboratories, 2014* 39
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by TCM Biotech International Corp, 2014* 40
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 41
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Phenex Pharmaceuticals AG, 2014* 42
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by GW Pharmaceuticals plc, 2014* 43
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Genextra S.p.a., 2014* 44
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Diabetes and Digestive and Kidney Diseases, 2014* 45
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Tabriz University of Medical Sciences, 2014* 46
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Third Military Medical University, 2014* 47
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Michigan, 2014* 48
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 49
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 50
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2014* 51
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014* 52
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Ahvaz Jundishapur University of Medical Sciences, 2014* 53
Fatty Liver Disease Therapeutics Clinical Trials Market, Global, Clinical Trials by Bambino Gesu Hospital and Research Institute, 2014* 54

List of Figures
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Fatty Liver Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Fatty Liver Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Fatty Liver Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Fatty Liver Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Fatty Liver Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Fatty Liver Disease Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, G7 Countries (%), 2014* 15
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Fatty Liver Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Fatty Liver Disease to Gastrointestinal Clinical Trials, E7 Countries (%), 2014* 18
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Fatty Liver Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Fatty Liver Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Fatty Liver Disease Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Fatty Liver Disease Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Fatty Liver Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Fatty Liver Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Fatty Liver Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Fatty Liver Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Fatty Liver Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 83

Read the full report:
Fatty Liver Disease Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/617103/Fatty-Liver-Disease-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Niagara Networks will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
We’ve been doing it for years, decades for some. How many websites have you created accounts on? Your bank, your credit card companies, social media sites, hotels and travel sites, online shopping sites, and that’s just the start. We do it often without even thinking about it, quickly entering our personal information, our data, in a plethora of systems. Sometimes we’re not even aware of the information we are providing. It could be very personal information (think of the security questions you ...
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management solutions, helping companies worldwide activate their data to drive more value and business insight and to transform moder...
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. Big Data at Cloud Expo - to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is...
IoT is fundamentally transforming the auto industry, turning the vehicle into a hub for connected services, including safety, infotainment and usage-based insurance. Auto manufacturers – and businesses across all verticals – have built an entire ecosystem around the Connected Car, creating new customer touch points and revenue streams. In his session at @ThingsExpo, Macario Namie, Head of IoT Strategy at Cisco Jasper, will share real-world examples of how IoT transforms the car from a static p...
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said “No to LUNs.” With Tintri they mana...
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, migrations, and degraded performance). Download Slide Deck: ▸ Here In his general session at 18th Cloud Expo, Scott Cleland, Senior Director of Product Marketing for the HGST Cloud Infrastructure Business Unit, discusse...
Whether they’re located in a public, private, or hybrid cloud environment, cloud technologies are constantly evolving. While the innovation is exciting, the end mission of delivering business value and rapidly producing incremental product features is paramount. In his session at @DevOpsSummit at 19th Cloud Expo, Kiran Chitturi, CTO Architect at Sungard AS, will discuss DevOps culture, its evolution of frameworks and technologies, and how it is achieving maturity. He will also cover various st...
If you had a chance to enter on the ground level of the largest e-commerce market in the world – would you? China is the world’s most populated country with the second largest economy and the world’s fastest growing market. It is estimated that by 2018 the Chinese market will be reaching over $30 billion in gaming revenue alone. Admittedly for a foreign company, doing business in China can be challenging. Often changing laws, administrative regulations and the often inscrutable Chinese Interne...
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with the 19th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world and ThingsExpo Silicon Valley Call for Papers is now open.
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2016 Silicon Valley. The 19th Cloud Expo and 6th @ThingsExpo will take place on November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Interne...
Complete Internet of Things (IoT) embedded device security is not just about the device but involves the entire product’s identity, data and control integrity, and services traversing the cloud. A device can no longer be looked at as an island; it is a part of a system. In fact, given the cross-domain interactions enabled by IoT it could be a part of many systems. Also, depending on where the device is deployed, for example, in the office building versus a factory floor or oil field, security ha...
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, will discuss how VPaaS enables you to move fast, creating scalable video experiences that reach your...
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes ho...
"We have several customers now running private clouds. They're not as large as they should be but it's getting there. The adoption challenge has been pretty simple. Look at the world today of virtualization vs cloud," stated Nara Rajagopalan, CEO of Accelerite, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.